BioTwin’s C$2.5 Million Financing Round

Fasken advised BioTwin in connection with this transaction.

On April 8, 2021, BioTwin, a Quebec-based biotechnology company, announced the completion of their pre-seed funding round.

The company raised a total of C$2.5 million with the support of private investors and various levels of government. Leading this financing round, BioTwin received support from CTS, a business accelerator in the field of medical technologies.

This financing will accelerate BioTwin’s development of an AI platform used to detect, predict and prevent patients’ health various conditions.

The Fasken team included Henrick Simard (Picture) and Vincent Laforest-Lapointe. 

 

Involved fees earner: Vincent Laforest-Lapointe – Fasken Martineau; Henrick Simard – Fasken Martineau;

Law Firms: Fasken Martineau;

Clients: BioTwin;

Author: Martina Bellini